ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

Eli Lilly (LLY) reported robust Q2 2025 results, surpassing revenue and EPS estimates ($15.56B, $6.31 respectively) and raising its full-year outlook, propelled by strong demand for Mounjaro and Zepbound. Despite this, LLY shares declined 14% following the release of less compelling late-stage trial data for its oral obesity drug, orforglipron, which showed 12% weight loss compared to a competitor's 15%, overshadowing current successes and raising concerns about the drug's projected $12 billion annual sales by 2030.

Analysis

Eli Lilly presented a strong operational quarter that was decisively overshadowed by concerns about its future growth pipeline, triggering a significant market repricing. The company's second-quarter 2025 results surpassed analyst expectations, with earnings per share of $6.31 (beating the $5.61 consensus) and revenue of $15.56 billion (beating the $14.75 billion estimate), representing year-over-year growth of 61% and 38% respectively. This performance was fueled by surging demand for its existing GLP-1 drugs, Mounjaro and Zepbound, which saw sales increase 68% and 172%. Consequently, Eli Lilly raised its full-year guidance for both revenue and earnings. Despite this fundamental strength, the stock declined 14% due to late-stage trial data for its experimental oral obesity pill, orforglipron. The drug showed a 12% weight loss, which is less efficacious than the 15% demonstrated by Novo Nordisk's injectable competitor, Wegovy. This underperformance has cast doubt on Wall Street's $12 billion annual sales projection for orforglipron by 2030, signaling that the market is heavily discounting future prospects in favor of immediate pipeline concerns.

Key Decisions for Investors

• Investors should weigh the opportunity to buy into Eli Lilly's robust current earnings and upgraded guidance at a lower valuation against the significant risk posed by the less competitive trial data for its key pipeline drug, orforglipron.
• It is prudent to re-evaluate long-term growth models for LLY, as the orforglipron efficacy data may cap its future market share and places the forecasted $12 billion in annual sales by 2030 in jeopardy.
• Consider monitoring the competitive landscape closely, as the absence of liver toxicity in orforglipron could still become a key differentiator against other oral weight-loss candidates, despite its lower efficacy compared to injectables.
• For investors seeking to maintain exposure to the GLP-1 theme while mitigating single-stock risk, a position in a diversified pharmaceutical ETF such as IHE or a specialized fund like OZEM could be a more cautious approach.